GDRX - TherapeuticsMD slips after Q4 earnings miss

The shares of TherapeuticsMD (TXMD -20.2%) are trading sharply lower in morning hours after the women’s healthcare company reported lower than expected financials for Q4 2021. Revenue for the quarter at $18.7M missed average estimates of analysts by as much as $10.7M after a decline of ~17% YoY. Main contributors to the topline, ANNOVERA, a hormone therapy combination to address vasomotor symptoms and the dyspareunia therapy, IMVEXXY brought $7.8M and $6.7M worth of product revenue with declines of ~14% YoY and ~24% YoY, respectively. Meanwhile, the net loss for the quarter rose ~2% YoY to $43M even as gross product margin held steady at 75% while operating expenses slipped ~5% YoY to $49.3M. At the end of the year, TherapeuticsMD (NASDAQ:TXMD) reported $65.1M of cash on hand, a ~19% decline from 2020 year-end. Commenting on the decision to amend credit terms with Sixth Street, Chief Executive Hugh O’Dowd identified the move

For further details see:

TherapeuticsMD slips after Q4 earnings miss